These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34390710)

  • 1. Integrating network pharmacology and experimental models to investigate the mechanisms of dihydroartemisinin in preventing NSCLC progression via mTOR/HIF-1α signaling.
    Li Y; Xiao X; Wang H; Zhou Q; Jin Z; Zhang Y; Wang Y; Yue F; Zhou S; Yang J
    Eur J Pharmacol; 2021 Oct; 909():174411. PubMed ID: 34390710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elucidating the mechanism of action of Isobavachalcone induced autophagy and apoptosis in non-small cell lung cancer by network pharmacology and experimental validation methods.
    Wang L; Wang Z; Ni Y; Wang X; Zhang T; Hu M; Lian C; Wang X; Zhang J
    Gene; 2024 Aug; 918():148474. PubMed ID: 38670393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells.
    Mi YJ; Geng GJ; Zou ZZ; Gao J; Luo XY; Liu Y; Li N; Li CL; Chen YQ; Yu XY; Jiang J
    PLoS One; 2015; 10(3):e0120426. PubMed ID: 25799586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydroartemisinin inhibits tumor progress via blocking ROR1-induced STAT3-activation in non-small cell lung cancer.
    Li Y; Sun H; Bai C; Hu Y; Tang J; Zhang Y; Chen J; Zhong Z; He Y; Hu K; Yang J
    Int Immunopharmacol; 2024 May; 133():112157. PubMed ID: 38678671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-224 aggravates cancer-associated fibroblast-induced progression of non-small cell lung cancer by modulating a positive loop of the SIRT3/AMPK/mTOR/HIF-1α axis.
    Zhang J; Han L; Yu J; Li H; Li Q
    Aging (Albany NY); 2021 Apr; 13(7):10431-10449. PubMed ID: 33819917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α.
    Biziotis OD; Tsakiridis EE; Ali A; Ahmadi E; Wu J; Wang S; Mekhaeil B; Singh K; Menjolian G; Farrell T; Abdulkarim B; Sur RK; Mesci A; Ellis P; Berg T; Bramson JL; Muti P; Steinberg GR; Tsakiridis T
    Mol Oncol; 2023 Nov; 17(11):2235-2256. PubMed ID: 37584455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway.
    Jin H; Jiang AY; Wang H; Cao Y; Wu Y; Jiang XF
    Mol Med Rep; 2017 Sep; 16(3):3475-3481. PubMed ID: 28713965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroartemisinin inhibits activation of the AIM2 inflammasome pathway and NF-κB/HIF-1α/VEGF pathway by inducing autophagy in A431 human cutaneous squamous cell carcinoma cells.
    Wang Y; Li Z; Teng M; Liu J
    Int J Med Sci; 2021; 18(12):2705-2715. PubMed ID: 34104103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydroartemisinin inhibits Lewis Lung carcinoma progression by inducing macrophages M1 polarization via AKT/mTOR pathway.
    Xiao X; Li Y; Wang Y; Zhang Y; Chen J; Liu W; Tang J; Yue F; Yang J
    Int Immunopharmacol; 2022 Feb; 103():108427. PubMed ID: 34922249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
    Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
    Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of miR-199a on rats with non-small cell lung cancer via regulating the HIF-1α/VEGF signaling pathway.
    Wang LM; Zhang LL; Wang LW; Zhu L; Ma XX
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10363-10369. PubMed ID: 31841190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systems pharmacology unravels the synergic target space and therapeutic potential of Rhodiola rosea L. for non-small cell lung cancer.
    Zhang X; Zhu J; Yan J; Xiao Y; Yang R; Huang R; Zhou J; Wang Z; Xiao W; Zheng C; Wang Y
    Phytomedicine; 2020 Dec; 79():153326. PubMed ID: 32992083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression.
    Chang YC; Chan YC; Chang WM; Lin YF; Yang CJ; Su CY; Huang MS; Wu ATH; Hsiao M
    Cancer Lett; 2017 Sep; 403():28-36. PubMed ID: 28610954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-κB/GLUT1 axis.
    Jiang J; Geng G; Yu X; Liu H; Gao J; An H; Cai C; Li N; Shen D; Wu X; Zheng L; Mi Y; Yang S
    Oncotarget; 2016 Dec; 7(52):87271-87283. PubMed ID: 27895313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
    Meng S; Wang G; Lu Y; Fan Z
    Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydroartemisinin suppresses glycolysis of LNCaP cells by inhibiting PI3K/AKT pathway and downregulating HIF-1α expression.
    Zhu W; Li Y; Zhao D; Li H; Zhang W; Xu J; Hou J; Feng X; Wang H
    Life Sci; 2019 Sep; 233():116730. PubMed ID: 31390552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydroartemisinin Increases the Sensitivity of Photodynamic Therapy Via NF-κB/HIF-1α/VEGF Pathway in Esophageal Cancer Cell in vitro and in vivo.
    Li Y; Sui H; Jiang C; Li S; Han Y; Huang P; Du X; Du J; Bai Y
    Cell Physiol Biochem; 2018; 48(5):2035-2045. PubMed ID: 30099443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melittin inactivates YAP/HIF-1α pathway via up-regulation of LATS2 to inhibit hypoxia-induced proliferation, glycolysis and angiogenesis in NSCLC.
    Li H
    Clinics (Sao Paulo); 2024; 79():100407. PubMed ID: 38889502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decoding potential targets and pharmacologic mechanisms of curcumin in treating non-small cell lung carcinoma via bioinformatics and molecular docking.
    Li J; Zhang Z; Zhao J; Liu S; Feng C; Deng H; Liu D; Zeng J; Yu Q; Zhou D; Zhu M; Liu Y
    Braz J Med Biol Res; 2024; 57():e13550. PubMed ID: 39258670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.